Spots Global Cancer Trial Database for The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice
Official Title: Prostate Cancer Risk Assessment Using Genetic Markers in General Practice
Study ID: NCT01739062
Conditions
Interventions
Study Description
Brief Summary: The preferred method for early detection of prostate cancer (PCa) in older men with family history is the Prostate Specific Antigen test (PSA test), although the method is imprecise. It produces a high number of false-positive results and increases the risk of over-diagnosis and over-treatment. Yet, an increasing number of men get the PSA test as part of unsystematic screening. Genetic risk assessment may be a better way to identify men with low risk of PCa. The main study hypothesis is that genetic information about low risk of PCa can reduce the number of patients who get a PSA test as part of unsystematic screening.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
Department of Molecular Medicine, Aarhus N, Aarhus, Denmark
Contact Details
Name: Karina D Sørensen, PhD
Affiliation: Department of Molecular Medicine, Aarhus University Hospital, Denmark
Role: PRINCIPAL_INVESTIGATOR
Name: Flemming Bro, Professor
Affiliation: The Research Unit for General Practice, Aarhus University, Denmark
Role: STUDY_CHAIR
Name: Peter Vedsted, Professor
Affiliation: Danish Research Centre for Cancer Diagnosis in Primary Care, Aarhus University, Denmark
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
